Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00277732
NCT00277732
Completed
Not Applicable

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

University Ghent1 site in 1 country288 target enrollmentJanuary 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetes Mellitus

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus
Sponsor
University Ghent
Enrollment
288
Locations
1
Primary Endpoint
The difference between the study groups in the change of blood glucose and HbA1c
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to the control group ( = no input from pharmacist) or intervention group ( = with pharmaceutical care at baseline and follow-up visits over 6 months).

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
November 2006
Last Updated
18 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •45-75 years
  • •Body Mass Index \>= 25
  • •Diabetes treatment for at least 12 months
  • •Regular visitors of the participating community pharmacy

Exclusion Criteria

  • •Patients taking only insulin (no oral antidiabetic drugs)

Outcomes

Primary Outcomes

The difference between the study groups in the change of blood glucose and HbA1c

Time Frame: baseline and after 6 months

Secondary Outcomes

  • Knowledge about diabetes and treatment(after 6 months)
  • Therapy adherence
  • Body Mass Index(after 6 months)
  • Periods of severe hypoglycemia
  • GP visits, emergency room visits and hospitalisations
  • Work days lost
  • Frequency of eye and foot examination

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCystic Fibrosis
NCT03911713Vertex Pharmaceuticals Incorporated77
Completed
Phase 2
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia Syndrome
NCT05633407argenx53
Active, not recruiting
Phase 1
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C Infectio
EUCTR2015-003006-16-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57
Active, not recruiting
Phase 1
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C Infectio
EUCTR2015-003006-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57
Active, not recruiting
Phase 1
The Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants with Chronic Hepatitis C InfectioChronic genotype 1 or genotype 4 Hepatitis C Virus infectionMedDRA version: 20.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2015-003006-16-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.57